Tempest Therapeutics reported a net loss of $10.86 million for the first quarter of 2025, with an operating loss of $10.936 million. The company ended the quarter with $21.511 million in cash and cash equivalents, a decrease from the previous quarter. Key developments include new amezalpat data, orphan drug designations for TPST-1495 and amezalpat, and progress towards a Phase 2 trial for TPST-1495.

Tempest Therapeutics reported a net loss of $41.8 million for the year ended 2024, an increase from $29.5 million in 2023. The company's cash and cash equivalents decreased to $30.3 million from $39.2 million at the end of 2023, primarily due to operating activities offset by proceeds from common stock issuance. Research and development expenses significantly increased to $28.5 million, driven by preparations for the pivotal Phase 3 trial of amezalpat.

Tempest Therapeutics reported a net loss of $10.6 million for the third quarter of 2024. The company ended the quarter with $22.1 million in cash and cash equivalents. They also received a 'Study May Proceed' letter from the FDA for their pivotal Phase 3 trial of amezalpat combination therapy.

Tempest Therapeutics reported positive survival data for amezalpat in first-line liver cancer patients and is advancing the program towards a pivotal study. The company ended the quarter with $31.1 million in cash and cash equivalents. Net loss for the quarter was $9.6 million, or $0.42 per share.

Tempest Therapeutics reported a net loss of $7.9 million for the first quarter of 2024. The company ended the quarter with $32.3 million in cash and cash equivalents and expects to fund operations into the second quarter of 2025.

Tempest Therapeutics reported positive data for TPST-1120 in liver cancer and is preparing for a pivotal Phase 3 trial. The company ended the year with $39.2 million in cash and cash equivalents.

Tempest Therapeutics reported data demonstrating superiority of TPST-1120 across multiple study endpoints in first-line hepatocellular carcinoma. As of November 7, 2023, preliminary cash and cash equivalents were $32.8 million. Net loss for the quarter ended September 30, 2023 was $6.8 million and $0.48 per share.

Tempest Therapeutics reported a net loss of $7.6 million, or $0.54 per share, for the quarter ended June 30, 2023. The company ended the quarter with $17.6 million in cash and cash equivalents. They also presented data from their TPST-1495 and TPST-1120 programs.

Tempest Therapeutics reported a net loss of $7.6 million, with cash and cash equivalents totaling $22.9 million at the end of the quarter. The company highlighted positive early data from its TPST-1120 study in HCC patients and presented new data on its TREX1 inhibitor program.

Tempest Therapeutics reported a net loss of $35.7 million for the year ended December 31, 2022. The company ended the year with $31.2 million in cash and cash equivalents.

Tempest Therapeutics reported a net loss of $8.9 million, or $0.66 per share, for the third quarter of 2022. The company ended the quarter with $42.8 million in cash and cash equivalents. Research and development expenses were $6.0 million, while general and administrative expenses were $2.8 million.

Tempest Therapeutics reported a net loss of $9.2 million, or $0.79 per share, for the second quarter of 2022. The company ended the quarter with $51.6 million in cash and cash equivalents. Research and development expenses were $5.7 million, while general and administrative expenses were $3.1 million.

Tempest Therapeutics reported a net loss of $8.5 million, or $1.18 per share, for the quarter ended March 31, 2022. The company ended the quarter with $45.8 million in cash and cash equivalents.

Tempest Therapeutics reported its year-end 2021 financial results, highlighting achievements such as becoming a public company and establishing a collaboration with Roche. The company ended the year with $51.8 million in cash and cash equivalents.

Tempest Therapeutics reported a net loss of $8.1 million, or $1.21 per share, for the third quarter of 2021. The company ended the quarter with $59.8 million in cash and cash equivalents. Research and development expenses were $4.6 million, and general and administrative expenses were $3.1 million.

Tempest Therapeutics reported financial results for Q2 2021, highlighting the closing of the merger transaction, resulting in a public listing and closing a $30M PIPE. The company's cash and cash equivalents increased to $68.5 million. Net loss was $7.1 million, or $7.63 per share.